| Mrs Jenna Ann Day, MA CCC-SLP | |
|
225 S. Main Street, 181 Polsky Bldg. The University Of Akron, Akron, OH 44325 | |
| (330) 972-6163 | |
| Not Available |
| Full Name | Mrs Jenna Ann Day |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 225 S. Main Street, Akron, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386060531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | S.P 11310 (Ohio) | Primary |
| Provider Name | The University Of Akron |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1326194812 PECOS PAC ID: 8921280751 Enrollment ID: O20110315000599 |
News Archive
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
In support of Rare Disease Day 2010, set for February 28, Lundbeck Inc. today launched the Raise Your Hand to Fight Rare Diseases campaign. The web-based initiative is designed to generate support for people with rare diseases and is being conducted in partnership with the National Organization for Rare Disorders (NORD), the sponsor of Rare Disease Day in the United States.
Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically ill patients admitted to the intensive care unit.
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jenna Ann Day, MA CCC-SLP 225 S. Main Street, 181 Polsky Bldg. The University Of Akron, Akron, OH 44325 Ph: (330) 972-6163 | Mrs Jenna Ann Day, MA CCC-SLP 225 S. Main Street, 181 Polsky Bldg. The University Of Akron, Akron, OH 44325 Ph: (330) 972-6163 |
News Archive
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
In support of Rare Disease Day 2010, set for February 28, Lundbeck Inc. today launched the Raise Your Hand to Fight Rare Diseases campaign. The web-based initiative is designed to generate support for people with rare diseases and is being conducted in partnership with the National Organization for Rare Disorders (NORD), the sponsor of Rare Disease Day in the United States.
Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically ill patients admitted to the intensive care unit.
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
› Verified 8 days ago
Michele Y Gunther, S.P.L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Jamie Blaylock, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 450 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-376-0153 | |
Kimberly Marie Gibbons, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2425 Foxboro Ave, Akron, OH 44305 Phone: 330-631-5678 | |
Kristin Weaver, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Mrs. Elizabeth Kinzig, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Wyant Rd, Akron, OH 44313 Phone: 330-836-7953 | |
Mrs. Andrea P. Brewer, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 181 Polsky Building, Akron, OH 44325 Phone: 330-972-8189 Fax: 330-972-7884 | |
Mary Mariani-walker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1199 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-873-3396 |